サンプル依頼リスト カート
  • English
  • Korean
表紙：副甲状腺機能亢進症治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1352139

副甲状腺機能亢進症治療の世界市場-2023年～2030年

Global Hyperparathyroidism Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
副甲状腺機能亢進症治療の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

副甲状腺機能亢進症は、個々の副甲状腺が血液中に多量の副甲状腺ホルモンを産生することで生じます。この副甲状腺は首の下の甲状腺の後ろにあり、米粒ほどの大きさです。副甲状腺機能亢進症には2つのタイプがあります。原発性副甲状腺機能亢進症では、1つ以上の副甲状腺の肥大が副甲状腺ホルモンの過剰分泌を引き起こします。そのため血液中のカルシウム濃度が高くなり、さまざまな健康障害を引き起こす可能性があります。原発性副甲状腺機能亢進症の治療は、手術が最も一般的です。

二次性副甲状腺機能亢進症は、最初に体内のカルシウム濃度が低くなる別の病気が原因で起こります。時間が経つにつれて、体がカルシウムレベルを標準範囲に保とうと闘うため、副甲状腺ホルモンのレベルが上昇します。これは腎臓病やある種の腸の手術や病気の後によく見られます。

副甲状腺機能障害の症状は軽度から重度まであり、骨粗鬆症から腎臓結石、過度の排尿、腹痛、脱力感、抑うつ、骨や関節の痛み、頻繁な病気の訴え、吐き気、嘔吐、食欲不振などがあります。

さらに、世界の副甲状腺機能亢進症市場は、認知度の向上や診断、研究開発、医療技術の進歩など、さまざまな要因によって牽引されており、予測期間中に市場が成長する原動力となっています。

ダイナミクス

副甲状腺がんの有病率の上昇

副甲状腺がんの有病率の上昇は、予測期間中に市場を成長させる重要な主要因の1つです。副甲状腺に発生するほぼすべての腫瘍は良性です。良性の副甲状腺腫瘍であっても迅速な医療が必要であることに注意することが重要です。完全に、あるいは適切に取り除かなければ、再発する可能性があり、コントロールが非常に難しくなります。この種の腫瘍は、コントロールが困難な高カルシウム血症を引き起こしたり、死に至ることもあります。

例えば、米国臨床腫瘍学会（ASCO）によると、副甲状腺がんはかなりまれです。米国で毎年診断される症例は100例未満であろう。この病気は30歳以上の高齢者に最も多く診断されます。男性も女性も同じように罹患します。予後（回復の可能性）は女性の方がやや良好です。

高齢者人口の増加

副甲状腺機能亢進症は高齢者に多く、世界の人口が高齢化するにつれて、この疾患の発生率は増加し、治療の必要性が高まると予測されています。例えば、National Library of Medicine 2022に掲載された論文によると、高齢者人口における原発性副甲状腺機能亢進症（PHPT）の有病率は、年齢が進むにつれて増加する一般的な疾患です。有病率のピークは、女性では70～79歳（10万人当たり492人）、男性では80歳以上（10万人当たり264人）です。

技術進歩の進展

副甲状腺機能低下症の治療のために、いくつかの市場企業が新しい技術の進歩を打ち出しています。手術は依然としてPHPTの決定的な治療法であり、スクリーニングの進歩、手術適応の進化、新たな画像診断法、術中法の改善により、状況は大きく変化しています。経験豊富な副甲状腺外科医の手にかかれば、手術はすばらしい結果をもたらし続けます。また、新しい画像診断技術や手術補助具の進歩もあり、病気の治療が進歩し続けています。

製品リコール

製品リコールや治療に伴ういくつかの副作用は、予測期間中の市場成長を妨げる要因の一部であり、一般的な合併症には、乳房の痛みや圧痛、めまい、頭痛などが含まれます。例えば、2019年9月、武田薬品工業株式会社はNATPARAの米国でのリコールを発表しました。このリコールは、NATPARAカートリッジのゴム製隔壁からゴム微粒子が上昇することに関連した潜在的な問題のためです。

また、在宅医療における遺伝子検査は、その利点にもかかわらず、患者の遺伝子情報のプライバシーや管理に対する懸念から、市場成長の妨げとなっています。これは、二次性副甲状腺機能亢進症の治療において特に重要であり、顧客は自分の遺伝物質や関連データの管理を放棄することになるからです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 副甲状腺がんの有病率の上昇
      • 高齢者人口の増加
      • 技術進歩
    • 抑制要因
      • 製品リコール
    • 機会
      • 民間組織と公的組織のコラボレーション・パートナーシップの増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • 二次性副甲状腺機能亢進症
  • 原発性副甲状腺機能亢進症

第8章 薬剤の種類別

  • カルシメティックス
  • ホルモン補充療法
  • ビスフォスフォネート製剤
  • その他

第9章 投与経路別

  • 経口
  • 非経口

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • OPKO Health
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Pfizer
  • Amgen
  • Abbvie
  • Dr Reddy's
  • Sanofi
  • Teva Pharmaceuticals
  • Merck KGaA
  • ONO Pharmaceuticals
  • Xediton Pharmaceuticals

第14章 付録

目次
Product Code: PH6870

Overview

Hyperparathyroidism occurs when individual parathyroid glands create high amounts of parathyroid hormone in the bloodstream. These glands, located behind the thyroid at the bottom of your neck, are about the size of a grain of rice. There are two types of hyperparathyroidism. In primary hyperparathyroidism, an enlargement of one or more of the parathyroid glands causes the overproduction of parathyroid hormone. This causes high calcium levels in the blood, which can cause a variety of health problems. Surgery is the most common treatment for primary hyperparathyroidism.

Secondary hyperparathyroidism occurs due to another disease that first causes low calcium levels in the body. Over time, increased parathyroid hormone levels occur as the body fights to keep the calcium level up in the standard range. This is common in kidney disease and after certain intestinal surgeries or diseases.

Symptoms of parathyroid dysfunction can be mild or severe, ranging from osteoporosis to kidney stones, excessive urination, abdominal pain, weakness, depression, bone and joint pain, frequent illness complaints, nausea, vomiting, or loss of appetite.

Furthermore, the global hyperparathyroidism market is driven by various factors like growing awareness and diagnosis, research and development, advancements in medical technology and others that will drive this market to grow during the forecast period.

Dynamics

Rise in The Prevalence of Parathyroid Cancers

The rise in the prevalence of parathyroid cancers is one of the significant key factors that drive the market to grow during the forecast period. Nearly all tumours that develop in the parathyroid gland are benign. It is important to note that even benign parathyroid tumours need prompt medical care. If they are not removed completely or properly, they can come back and be very difficult to control. This type of tumour may result in hypercalcemia of the blood that is difficult to control or could cause death.

For instance, according to the American Society of Clinical Oncology (ASCO), Parathyroid cancer is quite rare. There are likely fewer than 100 cases diagnosed each year in the United States. The disease is most often diagnosed in people older than 30. Men and women are equally affected. Women have a slightly better prognosis, which is the chance of recovery.

Rise in The Geriatric Population

Hyperparathyroidism is more frequent in elderly people, and as the world population ages, the condition's incidence is projected to grow, increasing the need for therapies. For instance, according to the article published in the National Library of Medicine 2022, the Prevalence of Primary Hyperparathyroidism (PHPT) in the geriatric population is a common disease that increases in prevalence with advancing age. Prevalence peaks in women around 70-79 years of age (492 per 100,000) and in men over 80 years old (264 per 100,000).

Rise in the Technological Advancements

Several market players are coming with new technology advancements for the treatment of hypoparathyroidism. Surgery remains the definitive treatment for PHPT, and advances in screening, evolving indications for surgery, new imaging modalities, and improvements in intra-operative methods have greatly changed the landscape. Surgery continues to produce excellent results in the hands of an experienced parathyroid surgeon. Also, there have been advancements in Newer imaging techniques and surgical adjuncts that continue to advance the cure of diseases.

Product Recalls

Product recalls and some side effects associated with the treatment are some of the restraints that hamper the market growth during the forecast period, the common complications include breast pain and tenderness, dizziness, headaches and others. For instance, in September 2019, Takeda Pharmaceutical Company Limited issued the U.S. recall of NATPARA. The recall is because of a potential issue associated with rubber particulates rising from the rubber septum of the NATPARA cartridge.

Also, Genetic tests in homecare settings, despite their benefits, hinder market growth due to concerns about privacy and control over patient genetic information. This is particularly important for secondary hyperparathyroidism treatment, as customers forfeit control over their genetic material and related data.

Segment Analysis

The global hyperparathyroidism treatment market is segmented based on type, drug type, route of administration, distribution channel and region.

The Secondary Hyperparathyroidism Segment From The Type Segment Accounted For Approximately 42.5 % of The Hyperparathyroidism Share

The secondary hyperparathyroidism segment from the type segment accounted for 42.5% and it is expected to be dominated during the forecast period. Secondary hyperparathyroidism occurs when the parathyroid glands become enlarged and release too much PTH, causing a high blood level of PTH.

For instance, Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalyst Pacific and DaVita Venture Group, and Launch Therapeutics, a clinical development company, announced a collaboration to advance phase 3 clinical trials for upacicalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Tx is backed by funds managed by global investment firm Carlyle and its life sciences franchise Abingworth.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, due to ongoing clinical trials, increasing thyroid-related diseases and increasing initiatives taken by pharmaceutical organizations to generate novel formulations.

For instance, according to the Clinical trial.gov reports an ongoing study titled 18F-Fluorocholine Positron Emission Tomography (PET) for Detecting Parathyroid Adenomas. The study aims to investigate the accuracy of PET in detecting hyperfunctioning parathyroid glands in surgical patients with primary hyperparathyroidism. The studies currently taking place at the University of California, San Francisco which is enrolled with 140 participants, currently where the study is expected to complete by June 2027.

Competitive Landscape

The major global players in the market include: OPKO Health, Pfizer, Amgen, Abbvie, Dr Reddy's, Sanofi, Teva Pharmaceuticals, Merck KGaA, ONO Pharmaceuticals, Xediton Pharmaceuticals and among others.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global hyperparathyroidism treatment market where, according to clinical trials.gov trials were getting conducted and where researchers evaluated the results of serum parathyroid hormone, calcium, phosphorus, and alkaline phosphatase tests in patients who were symptomatic and hospitalized with COVID-19 infection.

Participants also evaluated the relationship of parathormone with white blood cells, neutrophil/lymphocyte ratio, C reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone levels of patients with COVID-19 infection with the parathyroid hormone levels of healthy individuals without COVID-19 infection and parathyroid disease.

By Type

  • Secondary Hyperparathyroidism
  • Primary Hyperparathyroidism

By Drug Type

  • Calcimimetics
  • Hormone replacement therapy
  • Bisphosphonates
  • Others
  • Route of Administration
    • Oral
    • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In May 2023, Amolyt Pharma disclosed an oral presentation at the 25th European Congress of Endocrinology (ECE) 2023. The presentation emphasizes the potential benefits of eneboparatide as a therapy for hypoparathyroidism, a condition in which numerous people have or are susceptible to acquiring osteopenia and osteoporosis.
  • On August 2022, Ascendis Pharma A/S announced that it has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for Trans Con PTH, an investigational prodrug designed to restore parathyroid hormone to physiological levels over 24 hours in adult patients with hypoparathyroidism. Trans Con PTH has been granted Orphan designation in the United States and European Union.

Why Purchase the Report?

  • To visualize the global hyperparathyroidism treatment market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of hyperparathyroidism treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global hyperparathyroidism treatment market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in The Prevalence of Parathyroid Cancers
      • 4.1.1.2. Rise in The Geriatric Population
      • 4.1.1.3. Rise in the Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Product Recalls
    • 4.1.3. Opportunity
      • 4.1.3.1. A Rise in Collaboration Partnerships Between Private and Public Organizations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Secondary Hyperparathyroidism*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Primary Hyperparathyroidism

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.1.2. Market Attractiveness Index, By Drug Type
  • 8.2. Calcimimetics *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Hormone replacement therapy
  • 8.4. Bisphosphonates
  • 8.5. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parentral

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. OPKO Health*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Pfizer
  • 13.3. Amgen
  • 13.4. Abbvie
  • 13.5. Dr Reddy's
  • 13.6. Sanofi
  • 13.7. Teva Pharmaceuticals
  • 13.8. Merck KGaA
  • 13.9. ONO Pharmaceuticals
  • 13.10. Xediton Pharmaceuticals

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us